A new study is bringing interventional psychiatry research closer to explaining why medications with very different pharmacological targets may produce rapid antidepressant effects through overlapping biological processes. Published July 28, 2026, in Molecular Psychiatry, the research suggests that immune signaling may represent an important point of convergence between ketamine and serotonergic psychedelics.
Different Treatments May Arrive At The Same Destination
Ketamine and psychedelics such as psilocybin and LSD do not begin their actions in the same place. Ketamine is primarily associated with glutamatergic signaling, while classic psychedelics act largely through serotonin 5-HT2A receptors.
Yet both treatment classes have demonstrated the potential to produce relatively rapid changes in depressive symptoms. Previous randomized research, for example, found that a single 25 mg dose of psilocybin administered with psychological support reduced depression scores more than a 1 mg control dose at three weeks in adults with treatment-resistant depression.
The question is whether these pharmacologically distinct interventions eventually recruit some of the same downstream systems.
Neuroimmune Mechanisms Of Rapid Antidepressants Come Into Focus
Researchers led by Gregory H. Jones and colleagues investigated this possibility by integrating several forms of biological data rather than examining a single biomarker.
The study compared gene-expression changes in induced pluripotent stem cell-derived cortical neurons exposed to ketamine, the ketamine metabolite (2R,6R)-hydroxynorketamine, LSD, or psilocybin. Those findings were compared with protein changes in cerebrospinal fluid following intravenous ketamine.
The investigators then examined whether the resulting molecular patterns could also be detected in clinical data involving people with treatment-resistant depression and healthy volunteers.
This multilayered design incorporated whole-blood transcriptomics, plasma cytokines, clinical outcomes, and magnetoencephalography, or MEG, providing researchers with several independent windows into the biological response.
Immune Signaling Emerged As A Common Thread
Across the different compounds, researchers identified highly correlated transcriptional changes in the laboratory model.
A network of 103 proteins emerged from the comparison between neuronal gene-expression patterns and ketamine-associated cerebrospinal fluid changes. Within that network, immune-related signaling occupied a central position.
Two molecules were particularly notable: interleukin-15, or IL-15, and monocyte chemoattractant protein-1, also known as MCP-1 or CCL2.
Rather than appearing as isolated inflammatory markers, these molecules were positioned within networks connecting immune activity with synaptic, metabolic, and cellular signaling processes.
This raises the possibility that immune regulation is intertwined with the neuroplastic processes already thought to contribute to rapid antidepressant action.
Treatment Response Carried A Distinct Biological Signature
The researchers also observed differences between people who responded to ketamine and those who did not.
Before treatment, ketamine responders showed lower IL-15 pathway activity alongside increased B-cell signaling compared with non-responders. Following treatment, those patterns largely reversed.
Another immune signaling molecule, IL-7, was associated with MEG-measured gamma activity throughout the brain. The relationship was particularly pronounced in participants with treatment-resistant depression.
Following ketamine administration, the relationship changed direction, with IL-7 becoming associated with reductions in gamma activity across regions overlapping substantially with the default mode network.
Even more intriguingly, ratios involving IL-7, IL-15-related signaling, MCP-1, IL-4, and interferon gamma were associated with differences in antidepressant response.
From Inflammation To Immune Rebalancing
The findings suggest a more nuanced interpretation than simply describing depression as an inflammatory disorder.
Instead, therapeutic response could involve rebalancing specific immune pathways.
The authors propose that interactions between IL-7 and IL-15 signaling may influence B-cell regulation, immune-cell behavior, neuronal activity, and potentially the restructuring of brain networks following treatment.
Adenosine signaling also emerged as another candidate pathway shared by some rapid-acting antidepressants, although the researchers characterize those findings as exploratory and requiring direct validation.
Why This Study Stands Apart
One of the study’s strengths is its integration of biological measurements across multiple levels.
Rather than relying solely on blood biomarkers or brain imaging, the investigators combined cellular models, cerebrospinal fluid proteins, blood gene expression, circulating cytokines, clinical outcomes, and neurophysiology.
That convergence strengthens the rationale for investigating these pathways further, but it does not establish that altering IL-7 or IL-15 will itself treat depression.
The study also has meaningful limitations, including small samples for several analyses, exploratory transcriptomic thresholds, differences between biological datasets, and post-hoc analyses of previously completed clinical trials.
Toward Biomarker-Guided Rapid Antidepressant Treatment
The broader implication may ultimately concern precision psychiatry.
If immune signatures associated with response can eventually be replicated prospectively in larger populations, clinicians could potentially gain biomarkers that help identify which patients are more likely to benefit from particular rapid-acting interventions.
The findings could also help researchers investigate therapies capable of reproducing beneficial downstream mechanisms without necessarily reproducing every pharmacological or experiential feature of ketamine or psychedelics.
For now, the study provides a mechanistic framework rather than a clinical decision tool. Its significance lies in demonstrating that treatments beginning at very different receptors may nevertheless converge on shared neuroimmune biology, opening another avenue for understanding how rapid antidepressant effects emerge.
Citations
- Jones GH, Gilbert JR, Johnston JN, et al. “Convergent neuroimmune signaling underlying rapid antidepressant response to ketamine and psychedelics.” Molecular Psychiatry. Published July 28, 2026. Nature / Molecular Psychiatry Article
- Goodwin GM, Aaronson ST, Alvarez O, et al. “Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.” New England Journal of Medicine. 2022;387:1637-1648. DOI: 10.1056/NEJMoa2206443. New England Journal of Medicine Article
